Citryll Announces Formation of Scientific Advisory Board
CITRYLL ANNOUNCES FORMATION OF SCIENTIFIC ADVISORY BOARD
Board comprises world-renowned experts in biology, immunology and pathology
Citryll, a biotech company focused on innovative treatments for immune-mediated inflammatory diseases, has announced the establishment of its Scientific Advisory Board (SAB). This Board will offer crucial strategic guidance and scientific advice as Citryll advances the development of its first-in-class monoclonal antibody, CIT-013, aimed at addressing Neutrophil Extracellular Traps (NETs).
Expertise at the Core of the Advisory Board
The formation of this Board comes with the gathering of internationally recognized experts specializing in various aspects of NET biology, pre-clinical development, and immunology. Among the founding members are Dr. Tim Hammond, Professor John Hamilton, Dr. Christian Lood, and Professor Paul Kubes, each renowned for their significant contributions to medical research and drug development.
Welcoming Notable Members
"We are delighted to have such a prestigious group of experts join our Scientific Advisory Board," stated Eric Meldrum, Chief Scientific Officer of Citryll. Their extensive knowledge will be paramount in advancing CIT-013 through its clinical trials focusing on rheumatoid arthritis and hidradenitis suppurativa. With their collaboration, we expect to unlock a wealth of therapeutic potentials targeting extracellular traps in various inflammatory diseases, marking a significant milestone in expanding our advisory network as we pave the way for a Clinical Advisory Board aimed at enhancing our clinical trajectory.
Introducing the Scientific Advisory Board Members
Dr. Tim Hammond, PhD
Bringing over 35 years of expertise in pharmaceutical drug discovery, Dr. Hammond currently serves as Head of Safety across multiple organizations. His past tenure as Vice President of Safety Assessment for AstraZeneca in the UK highlights his remarkable capabilities. An esteemed independent consultant since 2012, he is lauded as a past President of the British Toxicology Society and a Fellow of the Royal College of Pathologists.
Professor John Hamilton, PhD
Prof. Hamilton is globally recognized for his influential research in macrophage biology and inflammation, with a remarkable focus on inflammatory diseases like rheumatoid arthritis. His accolades include significant awards from the Australian Rheumatology Association and the American College of Rheumatology.
Dr. Christian Lood, PhD
Dr. Lood is a leading figure in research on neutrophil function and NET formation, pivotal in understanding autoimmune diseases including systemic lupus erythematosus. He is currently an Associate Professor in the Division of Rheumatology at the University of Washington, dedicating his research to the interplay of neutrophils in various inflammatory conditions.
Professor Paul Kubes, PhD
Known for his groundbreaking work on leukocyte recruitment, Prof. Kubes is a professor at Queen’s University and holds a Canada Excellence Research Chair. His previous role as the Founding Director of the Snyder Institute for Chronic Disease at the University of Calgary underscores his influence in the field of inflammatory diseases.
About Citryll's Mission and Vision
Citryll stands at the forefront of developing transformative treatments targeting inflammatory diseases by focusing on the often-overlooked Neutrophil Extracellular Traps (NETs). This novel approach aims to create potential breakthrough therapies for a range of immune-mediated conditions.
The company is dedicated to advancing its lead product, CIT-013. This unique monoclonal antibody operates through a distinct dual mechanism by enhancing the clearance of existing NETs while inhibiting the formation of new ones.
By effectively targeting this essential driver of inflammation, CIT-013 aspires to provide an innovative and comprehensive treatment for conditions like rheumatoid arthritis and hidradenitis suppurativa, where existing therapies have often not achieved desirable disease management results.
Contact Citryll for More Information
Citryll
Sjoerd van Gorp, COO
Email: info@citryll.com
Citryll Media Contacts
ICR Healthcare
Amber Fennell, Stephanie Cuthbert, Lucy Featherstone
Email: citryll@icrinc.com
Frequently Asked Questions
What is the purpose of Citryll's Scientific Advisory Board?
The Scientific Advisory Board provides strategic guidance and scientific insights to aid in the development of Citryll's therapies, particularly CIT-013.
Who are the members of the Scientific Advisory Board?
The board includes experts such as Dr. Tim Hammond, Professor John Hamilton, Dr. Christian Lood, and Professor Paul Kubes.
What is CIT-013?
CIT-013 is Citryll's first-in-class monoclonal antibody that targets Neutrophil Extracellular Traps to treat inflammatory diseases.
How does CIT-013 work?
CIT-013 enhances the removal of existing NETs and prevents the formation of new ones, aiming to reduce inflammation in patients.
Where can I find more information about Citryll?
You can reach out to Citryll via email at info@citryll.com for detailed inquiries and information.
